SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aarti Drugs commences new R&D center at MIDC Tarapur

05 May 2014 Evaluate

Aarti Drugs has commenced the new R&D center at MIDC Tarapur. Earlier, on September 26, 2013  US health regulator had issued a warning letter to company's Maharashtra facilities .The investigators of the US Food and Drug Administration had identified significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals and active pharmaceutical ingredients at the companies Maharashtra facilities.

Aarti Drugs (ADL) is engaged in the business of manufacturing generic bulk actives, advanced intermediates and specialty chemicals. The company is part of $265 million Aarti Group of Industries.

Aarti Drugs Share Price

396.40 0.65 (0.16%)
10-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1935.25
Dr. Reddys Labs. 1245.50
Cipla 1438.75
Zydus Lifesciences 1150.50
Lupin 2496.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: